Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
07 3월 2025 - 9:20PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2025
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
7 March 2025
Notice of Annual General Meeting
AstraZeneca PLC (the Company) announced today the publication of
its Notice of Annual General Meeting 2025 and Shareholders'
Circular (the Notice).
The Company's Annual General Meeting (AGM) will be
digitally-enabled and will be held on Friday 11 April 2025 at 14:30
(BST). Full details and joining instructions are set out in the
Notice.
The Notice and proxy form for the AGM have been submitted to the
National Storage Mechanism and will shortly be available for
inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Notice is also available on the Company's website
at www.astrazeneca.com/noticeofmeeting2025.
The Notice is being despatched to shareholders today.
The business to be conducted at the AGM is summarised
below:
1.
To receive the Company's Accounts, the Reports of the
Directors and Auditor and the Strategic Report for the year ended
31 December 2024
2.
To confirm the 2024 interim dividends
3.
To re-appoint PricewaterhouseCoopers LLP as Auditor
4.
To authorise the Directors to agree the remuneration of the
Auditor
5.
To elect or re-elect Directors
6.
To approve the annual statement of the Chair of the
Remuneration Committee and the Annual Report on Remuneration for
the year ended 31 December 2024
7. To
authorise limited political donations
8.
To authorise the Directors to allot shares
9.
To authorise the Directors to disapply pre-emption
rights
10.
To authorise the Directors to further disapply pre-emption rights
for acquisitions and specified capital investments
11.
To authorise the Company to purchase its own shares
12. To
reduce the notice period for general meetings
Pursuant to Regulation 41 of the Uncertificated Securities
Regulations 2001, only holders of ordinary shares entered in the
register of members of the Company by 18:30 (BST) on 9 April 2025
(or their duly appointed proxies), or if this meeting is adjourned,
in the register of members by 18:30 (BST) two days prior to any
adjourned meeting, are entitled to attend or vote at the AGM in
respect of the number of ordinary shares registered in their name
at that time. Changes to the entries in the register of members
after 18:30 (BST) on 9 April 2025, or if this meeting is adjourned,
in the register of members after 18:30 (BST) two days prior to any
adjourned meeting, shall be disregarded in determining the rights
of any person to attend or vote at the AGM. The
Record Date applied to the Euroclear Sweden system to determine
entitlement to participate and vote at the AGM is close of business
on 2 April 2025. The
Record Date to determine entitlement to participate and vote at the
AGM for registered holders of the Company's American Depositary
Receipts is close of business on 25 February
2025.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative
medicines are sold in more than 125 countries and used by millions
of patients worldwide. Please visit astrazeneca.com and
follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
07 March 2025
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
AstraZeneca (NASDAQ:AZN)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
